P rostate cancer is the most commonly diagnosed cancer and the sixth leading cause of cancer-related death among men worldwide. 1 Strategies to block androgen-receptor signaling have formed the backbone of prostate-cancer therapy since the first description of the hormonal dependence of this cancer in 1941. 2 Advances in endocrine therapies have improved survival in men with high-risk locoregional prostate cancer. 3, 4 However, new hormonal agents have been shown to extend survival in men with metastatic castration-resistant disease. [5] [6] [7] [8] [9] In most patients who are treated for advanced recurrent prostate cancer with androgen-deprivation therapy (comprising a luteinizing hormonereleasing hormone [LHRH] analogue or orchiectomy with or without an antiandrogen), disease progression occurs despite effective suppression of serum testosterone. This disease state, called castration-resistant prostate cancer, is almost always associated with increases in levels of serum prostate-specific antigen (PSA), suggesting that the disease continues to be driven by androgen-receptor signaling. Preclinical evidence suggests that androgen-receptor overexpression is sufficient to confer resistance to androgen deprivation in prostate-cancer cell lines 10, 11 and that levels of intratumoral androgens are often increased in patients with progressive prostate cancer. 12 These observations have provided a clear basis for developing more effective methods to treat prostate cancer by further suppressing androgen-receptor signaling. 13, 14 Enzalutamide (formerly known as MDV3100) is a rationally designed, targeted androgen-receptor inhibitor that competitively binds to the ligand-binding domain of the androgen receptor and inhibits androgen-receptor translocation to the cell nucleus, recruitment of androgen-receptor cofactors, and androgen-receptor binding to DNA. 15 In a phase 1-2 trial, enzalutamide was found to have encouraging antitumor activity in men with castration-resistant prostate cancer, with data suggesting a greater benefit in men who had not yet received chemotherapy. 16 In a previous phase 3 study, enzalutamide, as compared with placebo, prolonged overall and progression-free survival, improved patient-reported quality of life, and delayed the development of skeletal-related complications in men with metastatic castrationresistant prostate cancer who had previously received docetaxel. 7 In our study, we evaluated enzalutamide in men in whom hormonal agents are frequently administered (i.e., those who have asymptomatic or mildly symptomatic metastatic disease that has progressed despite the use of androgen-deprivation therapy) and who have not undergone chemotherapy.
Me thods

Study Design and Conduct
The PREVAIL study was a multinational, doubleblind, randomized, placebo-controlled, phase 3 trial of enzalutamide. The study was approved by the independent review board at each participating site and was conducted according to the provisions of the Declaration of Helsinki and the Good Clinical Practice Guidelines of the International Conference on Harmonisation. All patients provided written informed consent before participating in the trial. An independent data and safety monitoring committee reviewed safety data at regular intervals and reviewed the prespecified interim analysis conducted by an independent statistical group at the contract clinical research organization where the study database was held.
The study was designed by prostate-cancer experts and employees of the sponsors, Medivation and Astellas Pharma, which are codeveloping enzalutamide. Investigators at the participating centers entered the data into an electronic data-capture system that was verified for source data by monitors from a separate clinical research organization. The data analyses reported here were conducted by the sponsor and were provided to all the authors, who wrote the manuscript and made the decision to submit the manuscript for publication. These authors assume responsibility for the accuracy of the data and adherence to the study protocol, which is available with the full text of this article at NEJM.org. A professional writer who was paid by the sponsors assisted in the preparation of the manuscript. All the authors and participating institutions have agreements with the sponsors regarding the confidentiality of the data.
Study Participants
Patients were eligible if they had histologically or cytologically confirmed adenocarcinoma of the prostate with documented metastases and had PSA progression, radiographic progression, or both in bone or soft tissue, despite receiving LHRH Patients with visceral disease, including lung or liver metastases, were eligible, as were patients with New York Heart Association class I or II heart failure. Patients with a history of seizure or a condition that could confer a predisposition to seizure were excluded, although patients taking medications associated with lowering the seizure threshold were eligible. From September 2010 through September 2012, patients were enrolled at 207 sites globally. All patients were randomly assigned to receive either oral enzalutamide (at a dose of 160 mg) or placebo once daily with or without food. Randomization was stratified according to the study site. Treatment continued until the occurrence of unacceptable side effects or confirmed radiographic progression and the initiation of chemotherapy or an investigational agent. Treatment discontinuation because of an increase in the PSA level alone was discouraged.
Study End Points
Coprimary end points were radiographic progression-free survival and overall survival. Secondary end points included the time until the initiation of cytotoxic chemotherapy, the time until the first skeletal-related event, the best overall soft-tissue response, the time until PSA progression, and a decline in the PSA level of 50% or more from baseline. Prespecified exploratory end points included quality of life, as measured with the use of the Functional Assessment of Cancer TherapyProstate (FACT-P) scale, and a decline in the PSA level of 90% or more from baseline. End-point definitions are provided in Table S1 in the Supplementary Appendix, available at NEJM.org.
Radiographic disease was evaluated with the use of either computed tomography or magnetic resonance imaging and with the use of bone scanning. Imaging was performed at the time of screening, at weeks 9, 17, and 25, and every 12 weeks thereafter. Radiologists at a central location who were unaware of the study-group assignments determined whether there was progressive disease on the basis of Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, for soft tissue or on the basis of criteria adapted from the Prostate Cancer Clinical Trials Working Group 2 17 for osseous disease (Table S1 in the Supplementary Appendix).
Statistical Analysis
The planned enrollment was approximately 1680 patients. The coprimary end points were analyzed in the intention-to-treat population at a total type I error rate of 0.05, with an error rate of 0.001 (two-sided) allocated to radiographic progression-free survival and an error rate of 0.049 (two-sided) allocated to overall survival. It was planned that the final analysis of radiographic progression-free survival would be conducted after the occurrence of at least 410 events at the time of the interim analysis of overall survival. The interim analysis of overall survival was to be conducted after the occurrence of approximately 516 deaths, or 67% of the 765 deaths specified for the final analysis. The final analysis of radiographic progression-free survival was performed after the occurrence of 439 events (with data cutoff on May 6, 2012); the interim analysis of overall survival was performed after the occurrence of 540 deaths with the use of a two-sided type I error rate of 0.0147. Holm's step-down procedure was applied to the analyses of the secondary end points to maintain a two-sided type I error of 5%. 18 The results presented here are based on a cutoff date of September 16, 2013, unless otherwise specified. An updated survival analysis was performed with a data-cutoff date of January 15, 2014.
R esult s
Study Patients
A total of 1717 patients were enrolled in the study, with 872 in the enzalutamide group and 845 in the placebo group; 1715 patients received at least one dose of a study drug (Fig. S1 in the Supplementary Appendix). Baseline demographic and disease characteristics were well balanced between the two groups (Tables S2 and S3 Supplementary Appendix). The median time that patients received a study drug was substantially longer in the enzalutamide group than in the placebo group (16.6 months vs. 4.6 months). More patients in the enzalutamide group than in the placebo group received at least 12 months of treatment (68% vs. 18%) and continued to receive treatment as of the data-cutoff date (42% vs. 7%).
Coprimary End Points
Radiographic Progression-free Survival
At 12 months of follow-up, the rate of radiographic progression-free survival was 65% in the enzalutamide group and 14% in the placebo group. most common subsequent therapies were docetaxel (received by 33% and 57% of patients, respectively) and abiraterone (received by 21% and 46%, respectively) ( Table S5 in the Supplementary Appendix). The use of abiraterone was more common in North America than in other regions. The duration and efficacy of post-progression therapies were not ascertained.
Prespecified Secondary and Exploratory End Points
The superiority of enzalutamide over placebo was shown with respect to all secondary end points. The median time until the initiation of cytotoxic chemotherapy was 28.0 months in the enzalutamide group, as compared with 10.8 months in the placebo group (hazard ratio, 0.35; P<0.001) (Table 1 and Fig. 2A) . Treatment with enzalutamide also resulted in a reduction in the risk of a first skeletal-related event, which occurred in 278 patients (32%) in the enzalutamide group and 309 patients (37%) in the placebo group (hazard ratio, 0.72; P<0.001) at a median of approximately 31 months in each of the two groups (Table 1) . Among patients with measurable soft-tissue disease at baseline, 59% of the patients in the enzalutamide group, as compared with 5% in the placebo group, had an objective response (P<0.001) ( Table 1) : complete and partial responses were observed in 20% and 39% of the patients, respectively, in the enzalutamide group, as compared with 1% and 4%, respectively, in the placebo group. Enzalutamide was also supe- Complete response 78 (20) 4 (1) Partial response 155 (39) 15 (4) rior to placebo with respect to reductions of at least 50% and 90% in the PSA level, the time until PSA progression, and the time until a decline in the quality of life (Table 1 and Fig. 2B ).
The median time until a quality-of-life deterioration, as measured on the FACT-P scale, was 11.3 months in the enzalutamide group and 5.6 months in the placebo group (hazard ratio, 0.63; P<0.001).
Safety
Adverse events are summarized in Tables 2 and 3 (with events occurring in at least 10% of patients in the enzalutamide group listed in the latter table). The median reporting period for adverse events was 17.1 months in the enzalutamide group and 5.4 months in placebo group, which reflected the longer exposure of patients to enzalutamide. A grade 3 or higher adverse event was reported in 43% of the patients in the enzalutamide group, as compared with 37% in the placebo group; however, the median time until the first event of grade 3 or higher was 22.3 months in the enzalutamide group and 13.3 months in the placebo group (Fig. S4 in the Supplementary Appendix). The most common adverse events leading to death were disease progression and a general deterioration in physical health, with similar incidences in the two groups. Adverse events that occurred in 20% or more of patients receiving enzalutamide at a rate that was at least 2 percentage points higher than that in the placebo group were fatigue (Table S6 in the Supplementary Appendix), back pain, constipation, and arthralgia. After adjustment for the length of exposure, events with a higher rate in the enzalutamide group than in the placebo group were hot flush (14 vs. 12 events per 100 patient-years), hypertension (11 vs. 7 events per 100 patient-years), and falls (11 vs. 9 events per 100 patient-years). The most common event of grade 3 or higher in the enzalutamide group was hypertension, which was reported in 7% of the patients. The most common cardiac event was atrial fibrillation, which was reported in 2% of the patients in the enzalutamide group and in 1% of those in the placebo group. One patient in each study group had a seizure. No evidence of hepatotoxicity, as measured by adverse events or laboratory assessments, was observed in the enzalutamide group.
Discussion
In our study involving men with metastatic prostate cancer who had not received previous chemotherapy, enzalutamide extended the time until radiographic progression or death, improved overall survival, and delayed the initiation of chemotherapy by a median of 17 months. The benefit of enzalutamide on radiographic progression-free survival was observed from the first assessment 2 months after randomization and conferred a relative reduction of 81% in the risk of progression or death. Consistent benefit was observed in all prespecified subgroups, including patients with visceral disease, a population with a poorer prognosis that has been excluded from other trials involving men with metastatic prostate cancer who have not received previous chemotherapy. 8, 19 Enzalutamide significantly reduced the risk of death by 29% over placebo, even though patients in the placebo group had received effective post-progression therapy more frequently and earlier than those in the enzalutamide group. The benefit of enzalutamide was observed as early as 4 months after randomization and was maintained throughout the study, as depicted by the separation in the Kaplan-Meier survival curves (Fig. 1B) . At the time the trial was halted, following the interim analysis, the median follow-up for survival was 22 months, approximately 8 to 10 months shorter than the estimated survival medians. Because less than 5% of the patients were at risk when the estimated medians were reached, the hazard ratio, which analyzes the differences in outcome across the entire follow-up period, is a more accurate characterization of the survival benefit and other late-occurring end points than is the estimate of the median time until the event.
Health-related quality-of-life assessments can reinforce and augment objective measures such as overall survival and radiographic progression. In this population of men with metastatic prostate cancer, deterioration in the quality of life was delayed by enzalutamide, a result suggesting that the treatment effects translated into patient-perceived benefits.
The benefit of enzalutamide was achieved with a favorable safety profile. Grade 3 or higher adverse events were more common in enzalutamide-treated patients than in placebo-treated patients (43% vs. 37%), a finding that was probably influenced by the fact that the safety-reporting period for the enzalutamide group was approximately 1 year longer than that for the placebo group. The safety profile is further illustrated by the 9-month delay in the median time until the first adverse event of grade 3 or higher in the enzalutamide group. A similar proportion of patients in each group (6%) discontinued treatment because of an adverse event.
The safety profile was generally consistent with that previously reported for enzalutamide in patients who had received previous chemotherapy, with a few exceptions. 7 Seizure, which was previously observed in the enzalutamide group among patients who had received chemotherapy, occurred in a single patient (0.1%) in each group in our study. Both patients had a history of seizure that was unknown to investigators at the time of enrollment. Hypertension was more commonly observed in the enzalutamide group than in the placebo group (13% vs. 4%) and occurred more often in patients with a medical history of hypertension. These events were not associated with symptoms of mineralocorticoid excess or an increased risk of cardiovascular or renal sequelae and generally were managed with the use of standard therapies. In contrast to other antiandrogens, enzalutamide was not associated with hepatotoxicity. Other adverse events that were reported more frequently in the enzalutamide group than in the placebo group included fatigue or asthenia, back pain, hot flush, and falls. Although chemotherapy has been shown to improve overall and progression-free survival in men with metastatic prostate cancer, 20,21 many patients do not receive such therapy primarily because of preexisting medical conditions or associated toxic effects. [22] [23] [24] Thus, there is a need for effective, convenient, and less toxic therapies. Sipuleucel-T showed an overall survival advantage in asymptomatic or mildly symptomatic men, most of whom had not received chemotherapy, but did not induce tumor responses or delay disease progression or deterioration in quality of life. 19 Radium-223 was recently shown to extend survival in men with symptomatic castration-resistant prostate cancer and bone metastases. 25 Abiraterone plus prednisone, which was recently compared with prednisone in patients with metastatic prostate cancer 8 who had not received chemotherapy, improved progression-free survival, lengthened the time until a quality-of-life deterioration, delayed chemotherapy use, and was associated with a trend in favor of an overall survival benefit that did not reach statistical significance. Treatment with abiraterone requires concomitant use of prednisone to ameliorate symptoms of mineralocorticoid excess, including fluid overload, hypokalemia, and hypertension. 8, 9 Multiple agents are now reported to improve survival for patients with metastatic prostate can- 
